Edward Tieng, MD
Urology · Knoxville, TNNPI 1184624140
Payments from drug & device makers
What this record shows
This record is dominated by education: $280 of the $317 with a category attached, or 88.5%. 4 manufacturers reported payments, led by Astellas Pharma US Inc at 57.3% of the total. 2022 is the largest year on record at $266, more than ten times the $15 reported in 2019. That places this record below the midpoint for urology clinicians in TN, where the typical reported total is $3,324.
Across 10 payments — averaging $31.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$182
- AbbVie$101
- Boston Scientific$19
- Pfizer$15
What the payments were for
- Food & beverage$3612%
- Education$28088%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $182 |
| AbbVie | 5 | $101 |
| Boston Scientific | 1 | $19 |
| Pfizer | 1 | $15 |
How this compares
$317 in reported general payments places this provider in the 20th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 15 | $210,410 |
| MyrbetriqMirabegron | 98 | $67,412 |
| GemtesaVibegron | 70 | $56,103 |
| Tamsulosin Hcl | 1,066 | $15,329 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 298 | $6,961 |
| Oxybutynin Chloride ErOxybutynin Chloride | 151 | $3,326 |
| Dutasteride | 101 | $2,855 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $2,015 |
| Testosterone Cypionate | 65 | $1,711 |
| Finasteride | 190 | $1,699 |
| Solifenacin Succinate | 32 | $1,624 |
| Bicalutamide | 26 | $1,217 |
| Cephalexin | 150 | $1,170 |
| Ciprofloxacin Hcl | 160 | $1,072 |
| Silodosin | 20 | $1,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $182 | $277,822113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 276 urology providers in Tennessee.
Other urology in Knoxville
- Edward KimKnoxville$52K
- Ryan PickensKnoxville$26K
- Paul HatcherKnoxville$26K
- James BienvenuKnoxville$19K
- Timothy LeroyKnoxville$18K
- Wesley WhiteKnoxville$13K
- Bruce WoodworthKnoxville$13K
- Walter ChilesKnoxville$13K
- L KnollNashville$2.1M
- David GubinMemphis$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.